Pediatric Tone Management




Tone management is one of the primary roles of a pediatric physiatrist. Hypertonicity frequently inhibits normal movement patterns in children with central nervous system lesions but at times can reinforce muscle group firing and be useful for a child’s function. Treatment approaches should be individualized based on functional goals, degree of impairment, interference with care, and type and location of hypertonicity. Treatment plans should be created in collaboration with all individuals caring for the child. There are many causes of hypertonicity as well as many nonsurgical and surgical treatments. Historical and current evidence-based treatments are reviewed.


Key points








  • The type of hypertonicity needs to be identified to determine optimal treatment.



  • Pediatric tone management involves all individuals caring for that child, including the patient, family, therapists, and the medical team.



  • There are multiple nonsurgical and surgical treatments for hypertonicity.






Introduction


Tone management is one of the primary roles of a pediatric physiatrist and is a rewarding but frequently challenging task. Hypertonicity frequently inhibits normal movement patterns in children with central nervous system (CNS) lesions. At times, hypertonicity can reinforce muscle group firing and be useful for a child’s function, such as stabilizing the lower limbs during stand pivot transfers. Hypertonicity can manifest as spasticity, dystonia, or rigidity, and frequently a combination is present. The manifestations of hypertonicity, underlying etiologies, and guiding treatment principles are reviewed.


Spasticity is probably the most common and easily recognizable form of hypertonicity. Spasticity is defined as increased muscle tone where resistance to externally imposed movement increases with increased speed of stretch and varies with the direction of joint movement. A child may experience difficulty with smooth movements because of spasticity. The muscle stretch reflex may be inadvertently triggered during activity, and the muscle “catch” may result in loss of postural stability. A commonly used scale to grade spasticity is the Modified Ashworth Scale using a range from 0 to 4, indicating no increased tone (0) to complete resistance to movement or rigidity (4).


Dystonia is a more complicated form of tone. It is characterized as increased muscle tone due to abnormal involuntary co-contractions in muscle groups causing repeated abnormal posturing of the neck, torso, or limbs. Dystonia is typically characterized as primary dystonia or secondary dystonia, which is typically due to an underlying cortical lesion in the thalamus or basal ganglia. Functionally, dystonia or dystonic movements increase when a child attempts to perform a novel or difficult task. Usually when the child is relaxed, there is no increased tone and all limbs may be freely mobilized. When the dystonia is active, the affected body areas or limbs twist into varied postures even when the child is performing a task with the unaffected limbs. Severe dystonia with co-contractions can present at rest with joint rigidity. Dystonia is commonly measured using the Fahn-Marsden (or Burke-Fahn-Marsden) rating scale or the Barry-Albright Dystonia Scale. The Fahn-Marsden scale ranges from 0 to 4, from no dystonia, dystonia with a particular action, dystonia on many actions, to dystonia at rest. Each limb and the trunk, head, and neck are evaluated. The Barry-Albright Dystonia scale also ranges from 0 to 4, but looks at the frequency of dystonia over 8 body regions.


A mixture of spasticity and dystonia is frequently present in children with more severe CNS lesions and is important to consider when treating tone disorders. Spasticity, dystonia, or a combination can lead to limb rigidity, which complicates treatment options.


Many pediatric conditions lead to hypertonicity, including cerebral palsy (CP), acquired brain injury, metabolic disorders, leukodystrophies, hydrocephalus, or spinal cord injury. CP is the most common condition associated with hypertonicity.


CP “describes a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to nonprogressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of CP are often accompanied by disturbances of sensation, perception, cognition, communication and behavior, by epilepsy, and by secondary musculoskeletal problems.” Tone and disorders of movement vary greatly among the CP population but most have some difficulties with limb hypertonicity. Cerebral vascular accidents, hypoxic ischemic events, hemorrhagic events related to extreme prematurity, traumatic brain injury, neonatal toxoplasmosis, other (syphilis, varicella-zoster, parvovirus B19), rubella, cytomegalovirus (CMV), and herpes infections (TORCH) infection, or isolated metabolic derangement injuries can lead to CP, highlighting the heterogeneity of this diagnosis. Neuronal migration abnormalities, such as schizencephaly, porencephaly, and polymicrogyria, may qualify under the CP diagnosis umbrella if no other genetic syndromes are associated.


When evaluating a child with newly noted hypertonicity, brain and spinal cord imaging should be considered to evaluate reversible etiologies. The American Academy of Neurology published a practice parameter guideline for “Diagnostic assessment of the child with cerebral palsy.” This guideline summary provides levels of evidence associated with workup measures for a child with suspected CP.


There are many causes of hypertonicity and a multitude of treatments to manage spasticity and dystonia. Treatment approaches should be individualized based on functional goals of the child and family, level of impairment, and/or ability to care for the child. The type, locality, and severity of hypertonicity need to be considered. Treatment plans should be created in collaboration with all individuals caring for the child, including the patient, family, therapists, and medical team.




Introduction


Tone management is one of the primary roles of a pediatric physiatrist and is a rewarding but frequently challenging task. Hypertonicity frequently inhibits normal movement patterns in children with central nervous system (CNS) lesions. At times, hypertonicity can reinforce muscle group firing and be useful for a child’s function, such as stabilizing the lower limbs during stand pivot transfers. Hypertonicity can manifest as spasticity, dystonia, or rigidity, and frequently a combination is present. The manifestations of hypertonicity, underlying etiologies, and guiding treatment principles are reviewed.


Spasticity is probably the most common and easily recognizable form of hypertonicity. Spasticity is defined as increased muscle tone where resistance to externally imposed movement increases with increased speed of stretch and varies with the direction of joint movement. A child may experience difficulty with smooth movements because of spasticity. The muscle stretch reflex may be inadvertently triggered during activity, and the muscle “catch” may result in loss of postural stability. A commonly used scale to grade spasticity is the Modified Ashworth Scale using a range from 0 to 4, indicating no increased tone (0) to complete resistance to movement or rigidity (4).


Dystonia is a more complicated form of tone. It is characterized as increased muscle tone due to abnormal involuntary co-contractions in muscle groups causing repeated abnormal posturing of the neck, torso, or limbs. Dystonia is typically characterized as primary dystonia or secondary dystonia, which is typically due to an underlying cortical lesion in the thalamus or basal ganglia. Functionally, dystonia or dystonic movements increase when a child attempts to perform a novel or difficult task. Usually when the child is relaxed, there is no increased tone and all limbs may be freely mobilized. When the dystonia is active, the affected body areas or limbs twist into varied postures even when the child is performing a task with the unaffected limbs. Severe dystonia with co-contractions can present at rest with joint rigidity. Dystonia is commonly measured using the Fahn-Marsden (or Burke-Fahn-Marsden) rating scale or the Barry-Albright Dystonia Scale. The Fahn-Marsden scale ranges from 0 to 4, from no dystonia, dystonia with a particular action, dystonia on many actions, to dystonia at rest. Each limb and the trunk, head, and neck are evaluated. The Barry-Albright Dystonia scale also ranges from 0 to 4, but looks at the frequency of dystonia over 8 body regions.


A mixture of spasticity and dystonia is frequently present in children with more severe CNS lesions and is important to consider when treating tone disorders. Spasticity, dystonia, or a combination can lead to limb rigidity, which complicates treatment options.


Many pediatric conditions lead to hypertonicity, including cerebral palsy (CP), acquired brain injury, metabolic disorders, leukodystrophies, hydrocephalus, or spinal cord injury. CP is the most common condition associated with hypertonicity.


CP “describes a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to nonprogressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of CP are often accompanied by disturbances of sensation, perception, cognition, communication and behavior, by epilepsy, and by secondary musculoskeletal problems.” Tone and disorders of movement vary greatly among the CP population but most have some difficulties with limb hypertonicity. Cerebral vascular accidents, hypoxic ischemic events, hemorrhagic events related to extreme prematurity, traumatic brain injury, neonatal toxoplasmosis, other (syphilis, varicella-zoster, parvovirus B19), rubella, cytomegalovirus (CMV), and herpes infections (TORCH) infection, or isolated metabolic derangement injuries can lead to CP, highlighting the heterogeneity of this diagnosis. Neuronal migration abnormalities, such as schizencephaly, porencephaly, and polymicrogyria, may qualify under the CP diagnosis umbrella if no other genetic syndromes are associated.


When evaluating a child with newly noted hypertonicity, brain and spinal cord imaging should be considered to evaluate reversible etiologies. The American Academy of Neurology published a practice parameter guideline for “Diagnostic assessment of the child with cerebral palsy.” This guideline summary provides levels of evidence associated with workup measures for a child with suspected CP.


There are many causes of hypertonicity and a multitude of treatments to manage spasticity and dystonia. Treatment approaches should be individualized based on functional goals of the child and family, level of impairment, and/or ability to care for the child. The type, locality, and severity of hypertonicity need to be considered. Treatment plans should be created in collaboration with all individuals caring for the child, including the patient, family, therapists, and medical team.




Nonsurgical management of hypertonicity


Nonsurgical management of spasticity and dystonia ranges from physical management to systemic medications and focal injections.


Physical Management of Hypertonicity


Physical management of focal and generalized hypertonicity continues to evolve over time and includes physical therapy, occupational therapy, orthoses, casting, modalities, and assistive technology. Early-intervention studies found that initiating services before 6 months of age was most effective. The most effective therapy approach for managing tone and impacting function is still unclear.


Passive stretch is a focal approach to tone management that increases range of motion and reduces spasticity. Spasticity is responsive to sustained stretch over several hours. Orthoses and casts are often used to reduce tone by reducing tonic stretch reflexes by prolonged static stretch. Caution should be used with certain orthoses, such as spring-assisted dorsiflexion, as they may exacerbate rapid stretch, triggering increased spasticity. Serial casting changes the number of sarcomeres and cross-bridge attachments in muscle. Serial casting also provides constant sensory input, which modulates the response of the muscle spindle and potentially decreasing spasticity.


Physical and occupational therapy techniques are based on different theories of motor learning to decrease generalized spasticity. In 2012, Franki and colleagues performed a systematic review of therapy techniques for tone management. They found neurodevelopmental treatment (NDT), functional and task-oriented training, and therapeutic horse riding or hippotherapy had Level IV evidence, hinting at the causality of reduction in spasticity. Dimitrijević and colleagues found a statistically significant reduction in spasticity in children with CP who participated in a twice-weekly aquatic therapy program for 12 weeks. Constraint-induced movement therapy (CIMT) may show functional benefits, but does not statistically change upper limb spasticity.


Modalities and manual therapies also have been used in attempts to reduce focal hypertonia. Therapeutic heat and ultrasound reduce tone by facilitating uptake of neurotransmitters and return of calcium to the sarcoplasmic reticulum. Therapeutic cold presumably reduces clonus by acting at the cutaneous mechanoreceptor level, which impacts interneuron excitatory presynaptic potentials at the spinal cord level. Cryotherapy reduces compound motor-action potentials, which reduces spasticity, but also decreases motor performance. Vibration, acupuncture, and craniosacral therapy have been used, but there are few data reflecting their efficacy on reduction of hypertonicity. Electrical stimulation produces a statistically significant reduction in spasticity immediately after stimulation. The effect of electrical stimulation on spasticity is thought to be due to secondary relaxation as a result of the habituation of the muscle spindle to the sensory stimulus.


Enteral Medications for Management of Spasticity


Benzodiazepines, such as diazepam, facilitate CNS inhibition via potentiation of gamma-aminobutyric acid (GABA) at the spinal and supraspinal levels, leading to a reduction in spasticity, hyperreflexia, and muscle spasms. Benzodiazepines also have been reported to help with sleep, decrease anxiety, and aid in management of seizures. Side effects include sedation, difficulty with consolidation and formation of new memory, urinary retention, liver toxicity, and dependency. Abrupt cessation of benzodiazepines may lead to agitation, tremor, muscle fasciculation, nausea, hyperpyrexia, and seizures. It is recommended to start with nightly dosing because of their sedating effects and titrate up to dosing twice a day to 3 times a day.


Baclofen binds to GABA B receptors and inhibits release of excitatory neurotransmitters and substance P, resulting in decreased spasms, clonus, and spasticity. Side effects include sedation, potential exacerbation of underlying seizure disorder, hypotonia, fatigue, nausea, and vertigo. Withdrawal from baclofen may lead to rebound spasticity, hypertension, hallucinations, seizures, and hyperpyrexia. Although baclofen has been found to be less sedating than diazepam, it is still recommended to begin with nightly dosing and titrate up to dosing twice a day to 3 times a day.


Dantrolene inhibits calcium release from the sarcoplasmic reticulum during muscle contraction. The effects are reduction in clonus and muscle spasms caused by innocuous stimuli. Dantrolene can be effective in athetoid CP. Side effects include mild sedation, although much less than diazepam and baclofen, malaise, nausea, vomiting, dizziness, diarrhea, and paresthesias. Hepatotoxicity can occur, so transaminase monitoring must be performed and is not dose dependent.


Tizanidine is an alpha-2 adrenergic agonist that acts at the spinal and supraspinal levels, leading to hyperpolarization of motor neurons to reduce spasticity. Side effects include sedation, hypotension, dry mouth, dizziness, and hepatotoxicity, so transaminase monitoring is recommended.


Tiagabine was originally used as an anticonvulsant, but it has been shown to be beneficial in reducing painful nocturnal spasms. It should be used with caution in those with hepatic insufficiency. Its side effects include dizziness, weakness, nausea, tremor, nervousness, confusion, difficulty with concentration, and abdominal pain. It is not recommended for children younger than 12 years.


Enteral Medications for Management of Dystonia


Much like spasticity, dystonia may be focal or generalized. Although treatment approaches for focal dystonia may include medications or focal injections, generalized dystonias in childhood should begin with a trial of dopaminergic agents. A dopa-responsive dystonia can be caused by a mutation of the GTP cyclohydrolase I gene on chromosome 14q, leading to an abnormality in dopamine synthesis. Symptoms include diurnal variation in dystonia and symptoms of parkinsonism. Dopa-responsive dystonia typically responds well to carbidopa/levodopa. Its side effects include dyskinesias, bradykinesia, hypotension, hallucinations, confusion, and memory impairment.


Trihexyphenidyl can be effective in the management of dystonia. Its side effects include dry mouth, blurred vision, urinary retention, anhidrosis, tardive dyskinesia, glaucoma, nausea, dizziness, anxiety, and neuroleptic malignant syndrome.


Baclofen also is used to treat dystonia, especially when carbidopa/levodopa and trihexyphenidyl fail to produce an adequate response. Higher doses are generally required to manage dystonia compared with spasticity.


Clonazepam, in combination with anticholinergic medications, has been helpful in treatment of myoclonus-dystonia.


Tetrabenazine and zolpidem have been trialed in treatment of dystonia. Tetrabenazine is an antidopaminergic drug that has been particularly helpful with tardive dystonia, but has many side effects, including transient acute dystonic reactions, insomnia, depression, and akathisia. Zolpidem, which has a high affinity for BZ1 receptors in the basal ganglia, has been effective in helping with some forms of dystonia.


Treatment for Focal Hypertonicity


In addition to physical modalities to help manage focal hypertonicity, certain medications may be injected, producing a neuromuscular blockage or chemodenervation within specific muscles to reduce focal spasticity or dystonia.


Chemodenervation through axonal degeneration may be accomplished using 3% to 5% phenol or 35% to 65% ethyl alcohol. These medications require localization using nerve stimulation or ultrasound for accurate perineural localization. The use of electric stimulation, the amount of time required for localization, and caustic effects of the medication cause pain and discomfort, especially in children, so sedation is often used. Care should be taken to avoid sensory and mixed sensorimotor nerves, because destruction of sensory fibers results in painful dysesthesias and numbness. Chemodenervation using phenol or ethyl alcohol is a cost-effective means of managing spasticity for 3 to 12 months with immediate effects.


Targeted injections of 5 to 10 mL of lidocaine 0.5% may provide temporary relief in focal dystonias, writer’s cramp, and oromandibular dystonias. The effects may last up to 24 hours, but can be lengthened to potentially several weeks with the addition of ethanol to the injection.


Neuromuscular blockade using botulinum toxin (BoNT) has been effective in managing focal spasticity, cervical dystonia, blepharospasms, oromandibular dystonia, and task-specific dystonias. The commercially available forms include onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and rimabotulinumtoxinB. All active forms of botulinum toxin are made of a heavy chain that binds to the presynaptic membrane. A zinc-dependent protease light chain cleaves the SNAP-25 protein in BoNT-A or the synaptobrevin-2 protein in BoNT-B, preventing acetylcholine vesicles from docking and releasing. Dosing regimens for the commercially available versions of botulinum toxin are not equivalent. The effects of botulinum toxin may be seen 5 to 7 days after injection and may last 3 to 6 months. Potential side effects include transient weakness, flulike symptoms, dysphagia, respiratory difficulties, transient ptosis, blurred vision, and hypophonia, depending on the sites injected. It has been found to have better efficacy when used in combination with other therapies.


Treatment Combinations


In a systematic review by Sakzewski and colleagues of intramuscular botulinum toxin A injections with CIMT, bimanual intensive training, or NDT; no treatment was superior. BoNT-A combined with other treatment approaches provided supplementary benefit. This was further demonstrated by Hoare and colleagues in 2010, who found improvements in range of motion with administration of BoNT-A injections in conjunction with occupational therapy. In 2007, Ronan and Gold found that kinesio-taping in combination with other tone-modifying agents can influence hypertonicity.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Apr 17, 2017 | Posted by in PHYSICAL MEDICINE & REHABILITATION | Comments Off on Pediatric Tone Management

Full access? Get Clinical Tree

Get Clinical Tree app for offline access